All News

Found 50 articles

• City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference

  12/8/2020

  City of Hope doctors participated in research presented at the American Society of Hematology (ASH) virtual meeting, Dec. 5 to 8, that are helping advance the treatment of blood cancers, including one study which demonstrated allogeneic stem cell transplants do have a survival benef

• US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and Exposition

  12/2/2020

  During the 62nd American Society of Hematology ( ASH ) Annual Meeting and Exposition, principal investigators from The US Oncology Network (The Network) and US Oncology Research will share detailed results from 30 studies covering topics that include Hodgkin lymphoma, multiple

• Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting

  11/5/2020

  – New data for Genentech’s CD20xCD3 bispecific antibodies will be featured, as well as first clinical data on cevostamab, a first-of-its-kind FcRH5xCD3 bispecific antibody, in multiple myeloma – – Longer-term data for Genentech’s approved therapies in hemophilia A, chronic lymphocytic leukemia and diffuse large B-cell lymphoma reinforce the favorable efficacy and safety profile of each medicine –

• Erasca Recruits Michael Varney, Ph.D., as Chairman of Research & Development and Scientific Advisory Board Member

  8/24/2020

  Erasca, a company whose mission is to erase cancer, today announced that Michael Varney, Ph.D., has joined the organization’s Scientific Advisory Board (SAB) and will also serve as Chairman of Research & Development (R&D). In these roles, Dr. Varney will help advance Erasca’s drug discovery portfolio by providing strategic input on portfolio o

• City of Hope Doctors Present Research on New Immunotherapies at American Society of Hematology Conference

  12/9/2019

  City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in Orlando presented research on novel chimeric antigen receptor (CAR) T therapy and other potential new therapies for blood cancers, as well as a comprehensive report on long-term health problems bone marrow transplant (BMT) survivors face and prevention efforts that can be taken.

• Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas

  12/7/2019

  Mosunetuzumab data to be presented at the American Society of Hematology 2019 Annual Meeting Plenary Scientific Session demonstrate durable complete responses in people with relapsed or refractory non-Hodgkin’s lymphoma

• Genentech to Present New Data Highlighting Breadth of Hematology Portfolio and Pipeline at the American Society of Hematology 2019 Annual Meeting

  11/6/2019

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines across a range of blood diseases will be presented at the 61st American Society of Hematology (ASH) Annual Meeting from December 7–10 in Orlando, Florida.

• City of Hope Clinical and Laboratory Investigators Present New Research at the 60th American Society of Hematology Meeting

  12/4/2018

  City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in San Diego presented clinical trials for new leukemia and lymphoma treatments, laying the groundwork for innovative therapeutic approaches aimed at improving treatment options and quality of life for patients.

• City of Hope Doctors Present New Research on CAR T Cell Therapy, Bone Marrow Transplants and Other Treatments for Blood Cancers

  11/19/2018

  Data will be presented at American Society of Hematology Annual Meeting Dec. 1-4

• Genentech to Present New Data from Its Industry-Leading Hematology Portfolio at the American Society of Hematology (ASH) 2018 Annual Meeting

  11/1/2018

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting